🇺🇸 FDA
Patent

US 11464856

Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11464856 (Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers) held by Julius-Maximilians-Universitat Wurzburg expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Julius-Maximilians-Universitat Wurzburg
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/55, A61K31/7105